Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial

被引:78
|
作者
Basch, Ethan [1 ,2 ]
Pugh, Stephanie L. [3 ]
Dueck, Amylou C. [4 ]
Mitchell, Sandra A. [5 ]
Berk, Lawrence [6 ]
Fogh, Shannon [7 ]
Rogak, Lauren J. [1 ]
Gatewood, Marcha [8 ]
Reeve, Bryce B. [2 ]
Mendoza, Tito R. [9 ]
O'Mara, Ann M. [5 ]
Denicoff, Andrea M. [5 ]
Minasian, Lori M. [5 ]
Bennett, Antonia V. [2 ]
Setser, Ann [10 ]
Schrag, Deborah [11 ]
Roof, Kevin [12 ]
Moore, Joan K. [13 ]
Gergel, Thomas [14 ]
Stephans, Kevin [15 ]
Rimner, Andreas [16 ]
DeNittis, Albert [17 ]
Bruner, Deborah Watkins [8 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, 170 Manning Dr, Chapel Hill, NC 27516 USA
[3] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA
[4] Mayo Clin, Alliance Stat & Data Ctr, Scottsdale, AZ USA
[5] Natl Canc Inst, Outcomes Res Branch, Div Canc Control & Populat Sci, Rockville, MD USA
[6] Univ S Florida, Radiat Oncol, Tampa, FL USA
[7] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
[8] Emory Univ, Nell Hodgson Woodruff Sch Nursing, Atlanta, GA 30322 USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
[10] Setser Hlth Consulting LLC, St Louis, MO USA
[11] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[12] NCORP, Southeast Community Canc Consortium Nation Canc, Southeast Radiat Oncol, Charlotte, NC USA
[13] Wellspan Adams Canc Ctr, Dept Oncol Adm, York, PA USA
[14] Geisinger Med Ctr, CCOP, Radiat Oncol, Danville, PA USA
[15] Cleveland Clin Fdn, Radiat Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA
[16] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA
[17] Main Line CCOP, Radiat Oncol, Wynnewood, PA USA
关键词
QUALITY-OF-LIFE; CHEMOTHERAPY; RELIABILITY; CANCER;
D O I
10.1016/j.ijrobp.2017.02.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To assess the feasibility of measuring symptomatic adverse events (AEs) in a multicenter clinical trial using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Methods and Materials: Patients enrolled in NRG Oncology's RTOG 1012 (Prophylactic Manuka Honey for Reduction of Chemoradiation Induced Esophagitis-Related Pain during Treatment of Lung Cancer) were asked to self-report 53 PRO-CTCAE items representing 30 symptomatic AEs at 6 time points (baseline; weekly x4 during treatment; 12 weeks after treatment). Reporting was conducted via wireless tablet computers in clinic waiting areas. Compliance was defined as the proportion of visits when an expected PRO-CTCAE assessment was completed. Results: Among 226 study sites participating in RTOG 1012, 100% completed 35-minute PRO-CTCAE training for clinical research associates (CRAs); 80 sites enrolled patients, of which 34 (43%) required tablet computers to be provided. All 152 patients in RTOG 1012 agreed to self-report using the PRO-CTCAE (median age 66 years; 47% female; 84% white). Median time for CRAs to learn the system was 60 minutes (range, 30-240 minutes), and median time for CRAs to teach a patient to self-report was 10 minutes (range, 2-60 minutes). Compliance was high, particularly during active treatment, when patients self-reported at 86% of expected time points, although compliance was lower after treatment (72%). Common reasons for noncompliance were institutional errors, such as forgetting to provide computers to participants; patients missing clinic visits; Internet connectivity; and patients feeling "too sick." Conclusions: Most patients enrolled in a multicenter chemoradiotherapy trial were willing and able to self-report symptomatic AEs at visits using tablet computers. Minimal effort was required by local site staff to support this system. The observed causes of missing data may be obviated by allowing patients to self-report electronically between visits, and by using central compliance monitoring. These approaches are being incorporated into ongoing studies. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:409 / 418
页数:10
相关论文
共 50 条
  • [1] DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE)
    Basch, E.
    Reeve, B.
    Cleeland, C.
    Sloan, J.
    Schrag, D.
    Atkinson, T. M.
    Mendoza, T.
    Hay, J.
    Abernethy, A.
    Minasian, L.
    Kwitkowski, V
    Trentacosti, A. M.
    Burke, L.
    Sit, L.
    Bruner, D.
    VALUE IN HEALTH, 2010, 13 (07) : A274 - A275
  • [2] DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS ( PRO-CTCAE)
    Basch, E.
    Reeve, B.
    Cleeland, C.
    Sloan, J.
    Mendoza, T.
    Abernethy, A.
    Bruner, D.
    Hay, J.
    Atkinson, T.
    Sit, L.
    Minasian, L.
    O'Mara, A.
    Burke, L.
    Schrag, D.
    VALUE IN HEALTH, 2010, 13 (03) : A44 - A44
  • [3] Development of the Patient-Reported Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
    Basch, Ethan
    Reeve, Bryce
    Cleeland, Charles S.
    Sloan, Jeff A.
    Schrag, Deborah
    Atkinson, Thomas M.
    Mendoza, Tito R.
    Hay, Jennifer L.
    Abernethy, Amy P.
    Minasian, Lori
    Kwitkowski, Virginia
    Trentacosti, Ann Marie
    Burke, Laurie
    Sit, Laura
    Bruner, Deborah W.
    QUALITY OF LIFE RESEARCH, 2010, 19 : 50 - 51
  • [4] Development of the patient-reported version of the common terminology criteria for adverse events (PRO-CTCAE)
    Basch, E. M.
    Reeve, B. B.
    Cleeland, C. S.
    Sloan, J. A.
    Mendoza, T. R.
    Abemethy, A. P.
    Bruner, D.
    Minasian, L. M.
    Burke, L. B.
    Schrag, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™)
    Hagelstein, V.
    Ortland, I.
    Wilmer, A.
    Mitchell, S. A.
    Jaehde, U.
    ANNALS OF ONCOLOGY, 2016, 27 (12) : 2294 - 2299
  • [6] Validation study of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
    Dueck, A. C.
    Mendoza, T. R.
    Reeve, B. B.
    Sloan, J. A.
    Cleeland, C. S.
    Hay, J.
    Li, Y.
    O'Mara, A. M.
    Denicoff, A.
    Basch, E. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Validity and reliability of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
    Dueck, Amylou C.
    Mendoza, Tito R.
    Mitchell, Sandra A.
    Reeve, Bryce B.
    Castro, Kathleen M.
    Denicoff, Andrea
    O'Mara, Ann M.
    Rogak, Lauren J.
    Clauser, Steven B.
    Bryant, Donna M.
    Gillis, Theresa A.
    Bearden, James D.
    Siegel, Robert D.
    Harness, Jay K.
    Paul, Diane B.
    Cleeland, Charles S.
    Sloan, Jeff A.
    Schrag, Deborah
    Minasian, Lori M.
    Basch, Ethan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] METHODS FOR REPORTING THE PATIENT-REPORTED OUTCOMES VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE) DATA IN CANCER CLINICAL TRIALS
    Zhou, X.
    Eid, D.
    Gnanasakthy, A.
    VALUE IN HEALTH, 2018, 21 : S226 - S226
  • [9] Psychometric validity of the Japanese version of Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
    Azuma, Kanako
    Kawaguchi, Takashi
    Miyaji, Tempei
    Sano, Motohiko
    Kim, Soan
    Kawahara, Yosuke
    Torii, Ayako
    Yamada, Yuri
    Hirata, Taiki
    Ishibashi, Keiichiro
    Okubo, Atsushi
    Basch, Ethan
    Yamaguchi, Takuhiro
    QUALITY OF LIFE RESEARCH, 2017, 26 (01) : 100 - 101
  • [10] A pilot study of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in a phase I clinical trial
    Qin, Rui
    Dueck, Amylou C.
    Satele, Daniel
    Molina, Julian R.
    Erlichman, Charles
    Basch, Ethan M.
    Sloan, Jeff A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)